Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer

PURPOSE: The Radiation Therapy Oncology Group (RTOG) multi-institutional Phase II study 98-12, evaluating paclitaxel and concurrent radiation (RT) for locally advanced pancreatic cancer, demonstrated a median survival of 11.3 months and a 1-year survival of 43%. The purpose of the randomized Phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Rich, Tyvin A, Winter, Kathryn, Safran, Howard, Hoffman, John P, Erickson, Beth, Anne, Pramila R, Myerson, Robert J, Cline-Burkhardt, Vivian JM, Perez, Kimberly, Willett, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430391/
https://www.ncbi.nlm.nih.gov/pubmed/22977306
http://dx.doi.org/10.2147/OTT.S33560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430391/
https://www.ncbi.nlm.nih.gov/pubmed/22977306
http://dx.doi.org/10.2147/OTT.S33560

Ejemplares similares